[Efficiency, effectiveness and safety of mechanical ventricular assistance with HeartWare® device in terminal heart failure]
Puñal-Riobóo J, Varela-Lema L, Atienza Merino G.
Record ID 32015000395
Spanish
Authors' objectives:
At worldwide level, heart failure (HF) is a major health problem that generates a considerable impact on health-care costs and patients' lives. Indeed, it is estimated to affect over 23 million people around the world. In Spain, the prevalence of HF stands at around 7% among people aged 45 years and older, rising to 16% among people aged 75 years and older. Furthermore, HF is the third leading cause of cardiovascular death, responsible for 11.5% and 16.8% of all deaths in men and women respectively. While cardiac transplantation is currently considered the treatment of choice for patients with advanced HF refractory to medical management, it is nevertheless limited by the availability of organs. In this context, 3rd-generation left ventricular assist devices (LVADs), such as the HeartWare® Ventricular Assist Device (HVAD), could afford an acceptable treatment option for the purpose of increasing survival among this group of patients.
The objective of this study was to assess the effectiveness and safety of the HVAD in the treatment of adult patients with advanced heart failure.
Authors' recommendations:
Despite its substantial adverse event rate, the HeartWare® LVAD registers a survival rate which is comparable to the HeartMate® LVAD. Accordingly, for patients with advanced, refractory HF, the HeartWare® LVAD may be regarded as an acceptable treatment option as a bridge to transplantation.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://avalia-t.sergas.es/DXerais/551/avalia-t201501HeartwareAsistVentricular_DEF.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Spain
MeSH Terms
- Heart-Assist Devices
- Treatment Outcome
Contact
Organisation Name:
Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
Contact Address:
Conselleria de Sanidade, Xunta de Galicia, San Lazaro s/n 15781 Santiago de Compostela, Spain. Tel: 34 981 541831; Fax: 34 981 542854;
Contact Name:
avalia-t@sergas.es
Contact Email:
avalia-t@sergas.es
Copyright:
Galician Agency for Health Technology Assessment (AVALIA-T)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.